This release offers few details on the actual benefits and evidence of wearing colored lenses to reduce light sensitivity following a concussion. There is no cost information, no comparison to alternatives (although alternatives are mentioned), no specific results on how patients fared in reducing light sensitivity and little in the way of description of the study.
To the casual reader, one might think that there’s a story here. But that’s what makes the lack of information so problematic. One can almost see the headlines: “Have a concussion? Look at life through rose-colored glasses.” With no proof in this release, reporters and readers can be misled into thinking that these findings are a bigger deal than they really are.
Photophobia, or sensitivity to light, is a common symptom in the days or weeks following a traumatic brain injury. If the study results hold up in larger trials, wearing colored glasses instead of dark sunglasses indoors to reduce headaches could be a useful solution for this temporary condition.
There is no mention of costs in the release.
The study provides no actual numbers to back up the claim that 85 percent of the patients had improvements in their symptoms. The only hard number it mentions is “51 patients.” But the study itself says, “Of the 39 patients studied who had vision symptoms, 76% complained of photophobia…symptoms were relieved in 85% of patients reporting photophobia.” So first that drops the number to 30 (depending on how they rounded). Then, 85 percent of that would be 26 (generously rounding up), which is a pretty small number. Not to mention that we have no idea what relief of symptoms means. And for how long did these symptoms go away?
The release says that there were no reported side effects while wearing colored glasses. It recommends against wearing colored glasses while driving since “certain colors make seeing stop lights or emergency vehicle lights difficult.”
The true size of the study is obscured. There’s no sense of the duration. And there’s no explanation of the methodology.
We did not find any disease mongering in the piece. Concussion and TBI numbers are very tricky because so few concussions are actually captured. TBIs are mostly tracked through ER visits. The CDC puts the TBIs that lead to ER visits at 2.8 million annually. So given that there are likely more mild concussions than true TBIs, this puts the 3.8 million number into conservative territory — if not well below where it should be.
The release states, “There was no funding used for this study.”
The release mentions some alternatives for finding relief from photophobia:
“In addition to trying colored-lens sunglasses, the article suggests other ways to mitigate photophobia including wearing a wide-brimmed hat when outdoors, adjusting digital screen and device settings to an appropriate hue and brightness or purchasing filters for screens.”
The release also notes that people find some relief by wearing dark sunglasses.
These lenses are presumably available at optical shops, but it’s unclear from the release.
The release doesn’t tell us if testing different colored lenses on people with concussions is novel research. It does say that researchers found that “wearing certain color-tinted sunglasses may be a good alternative to dark sunglasses.”
We find the language largely descriptive and not overly effusive beyond what appears to be supported by the study, however limited in scope it is.
This release from Johns Hopkins reports on a small, preliminary trial that shows adding a…
This news release from the FDA announces the agency’s approval of a new drug, dupilumab…
The news release describes an interesting new technology that uses computer technology to try to…
Systematic, Criteria-Driven
We will not display your name or e-mail address on the site, nor will we share your e-mail address with any third parties.
Thank you for joining the HealthNewsReview.org mailing list. It’s a good way for you to stay up-to-date on what we’ve published, even if you forget to come to our website every day or every week.
-Gary Schwitzer, Publisher, HealthNewsReview.org
By submitting this form, you are granting: HealthNewsReview.org, University of Minnesota , Minneapolis, MN, 55455, United States, https://www.healthnewsreview.org permission to email you. You may unsubscribe via the link found at the bottom of every email. Emails are serviced by Mailchimp. (See their Email Privacy Policy for details.)
This release from Johns Hopkins reports on a small, preliminary trial that shows adding a…
This news release from the FDA announces the agency’s approval of a new drug, dupilumab…
The news release describes an interesting new technology that uses computer technology to try to…
AP’s story on cancer immunotherapy quickly mentions low success rate https://t.co/pr233pNruz
Comments
We Welcome Comments. But please note: We will delete comments left by anyone who doesn’t leave an actual first and last name and an actual email address.
We will delete comments that include personal attacks, unfounded allegations, unverified facts, product pitches, or profanity. We will also end any thread of repetitive comments. Comments should primarily discuss the quality (or lack thereof) in journalism or other media messages about health and medicine. This is not intended to be a forum for definitive discussions about medicine or science. Nor is it a forum to share your personal story about a disease or treatment -- your comment must relate to media messages about health care. If your comment doesn't adhere to these policies, we won't post it. Questions? Please see more on our comments policy.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like
This release from Johns Hopkins reports on a small, preliminary trial that shows adding a…
This news release from the FDA announces the agency’s approval of a new drug, dupilumab…
The news release describes an interesting new technology that uses computer technology to try to…